Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 165 matching drugs for ATP1A1 — including drugs targeting any of its 57 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
digoxin, 5fluorouracil, calcium leucovorin, irinotecan, oxaliplatin ATP1A1 Direct 1
acetyldigitoxin ATP1A1 Direct yes 0
deslanoside ATP1A1 Direct yes 0
digitoxin ATP1A1 Direct yes 0
digoxin ATP1A1 Direct yes 0
adagrasib KRAS SSL via KRAS yes 2
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
sotorasib KRAS SSL via KRAS yes 2
lazertinib and amivantamab EGFR SSL via EGFR 1
osimertinib EGFR SSL via EGFR yes 1
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERBB2 SSL via ERBB2 3
afatinib ERBB2 SSL via ERBB2 yes 3
mrtx849, pembrolizumab, cetuximab, afatinib ERBB2 SSL via ERBB2 3
trastuzumab emtansine ERBB2 SSL via ERBB2 yes 3
tucatinib ERBB2 SSL via ERBB2 yes 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ERBB2 SSL via ERBB2 2
bryostatin 1, paclitaxel CCND1 SSL via CCND1 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab ERBB2 SSL via ERBB2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib ERBB2 SSL via ERBB2 2
lapatinib ERBB2 SSL via ERBB2 yes 2
olaparib PARP3 SSL via PARP3 2
radiotherapy targeted to the primary lesion, radiotherapy targeted to the metastatic lesions, anti-pd-1 monoclonal antibody, trastuzumab, chemotherapy, r0 total/subtotal gastrectomy with d2 lymphadenectomy, metastasectomy, local ablative therapies ERBB2 SSL via ERBB2 2
trastuzumab ERBB2 SSL via ERBB2 yes 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy ERBB2 SSL via ERBB2 2
trastuzumab, tipifarnib ERBB2 SSL via ERBB2 2
18f-fluoromisonidazole, cediranib maleate, laboratory biomarker analysis, olaparib, positron emission tomography PARP3 SSL via PARP3 1
2b3-101, trastuzumab, 2b3-101 60 mg/m2 every 4 weeks, 2b3-101 50 mg/m2 every 3 weeks ERBB2 SSL via ERBB2 1
5-fu, leucovorin, docetaxel, oxaliplatin (flot), trastuzumab, post-operative treatment trastuzumab mono therapy ERBB2 SSL via ERBB2 1
afatinib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging ERBB2 SSL via ERBB2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ERBB2 SSL via ERBB2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib PARP3 SSL via PARP3 1
afatinib, docetaxel, radiation therapy ERBB2 SSL via ERBB2 1
afatinib, gefitinib ERBB2 SSL via ERBB2 1
afatinib, irinotecan ERBB2 SSL via ERBB2 1
alisertib AURKA SSL via AURKA 1
alisertib, gemcitabine AURKA SSL via AURKA 1
arsenic trioxide CCND1 SSL via CCND1 1
arsenic trioxide, radiation therapy CCND1 SSL via CCND1 1
arsenic trioxide, temozolomide, adjuvant therapy, intensity-modulated radiation therapy, radiation therapy CCND1 SSL via CCND1 1
ascorbic acid, paclitaxel protein-bound, cisplatin, gemcitabine OGFOD1 SSL via OGFOD1 1
azd1775, olaparib PARP3 SSL via PARP3 1
bevacizumab, cediranib, cediranib maleate, olaparib PARP3 SSL via PARP3 1
biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, olaparib PARP3 SSL via PARP3 1
biopsy, biospecimen collection, computed tomography, magnetic resonance imaging, olaparib, pembrolizumab PARP3 SSL via PARP3 1
biopsy, biospecimen collection, echocardiography, pertuzumab, radiologic examination, trastuzumab ERBB2 SSL via ERBB2 1
biospecimen collection, computed tomography, magnetic resonance imaging, olaparib, placebo administration PARP3 SSL via PARP3 1
capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab ERBB2 SSL via ERBB2 1
capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab PARP3 SSL via PARP3 1
carboplatin, laboratory biomarker analysis, paclitaxel, quality-of-life assessment, radiation therapy, therapeutic conventional surgery, trastuzumab ERBB2 SSL via ERBB2 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin CCND1 SSL via CCND1 1
ceralasertib, olaparib, durvalumab PARP3 SSL via PARP3 1
cetuximab, trastuzumab ERBB2 SSL via ERBB2 1
cisplatin, 5-fluorouracil or capecitabine, trastuzumab, pertuzumab, gastrectomy ERBB2 SSL via ERBB2 1
cobimetinib, olaparib, onvansertib, azenosertib, saruparib, tremelimumab PARP3 SSL via PARP3 1
db-1310, trastuzumab, osimertinib ERBB2 SSL via ERBB2 1
disitamab vedotin, tucatinib ERBB2 SSL via ERBB2 1
disulfiram, copper, alkylating agents HTT SSL via HTT 1
docetaxel, leucovorin, fluorouracil, cisplatin, docetaxel, cisplatin, fluorouracil, neulasta, or neupogen, docetaxel, leukvorin, flurouracil, cisplatin, trastuzumab ERBB2 SSL via ERBB2 1
docetaxel, oxaliplatin, capecitabine, trastuzumab ERBB2 SSL via ERBB2 1
durvalumab, olaparib PARP3 SSL via PARP3 1
durvalumab, olaparib, cediranib PARP3 SSL via PARP3 1
enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) AURKA SSL via AURKA 1
enzastaurin, lomustine AURKA SSL via AURKA 1
enzastaurin, temozolomide, radiation therapy AURKA SSL via AURKA 1
ep0057, olaparib PARP3 SSL via PARP3 1
eras-007, encorafenib, cetuximab, palbociclib CCND1 SSL via CCND1 1
evorpacept (alx148), trastuzumab, ramucirumab, paclitaxel ERBB2 SSL via ERBB2 1
fluorouracil (5-fu), capecitabine, durvalumab, oxaliplatin, trastuzumab, trastuzumab deruxtecan, cisplatin, pembrolizumab, volrustomig, rilvegostomig ERBB2 SSL via ERBB2 1
fluorouracil, irinotecan sucrosofate, laboratory biomarker analysis, leucovorin calcium, rucaparib PARP3 SSL via PARP3 1
genistein, erlotinib hydrochloride, gemcitabine hydrochloride ESRRB SSL via ESRRB 1
hyperfractionated radiation therapy, stereotactic radiosurgery, alisertib, quality-of-life assessment AURKA SSL via AURKA 1
laboratory biomarker analysis, lapatinib, lapatinib ditosylate, pharmacological study, therapeutic conventional surgery ERBB2 SSL via ERBB2 1
lapatinib, chemoradiation, placebo ERBB2 SSL via ERBB2 1
lapatinib, placebo ERBB2 SSL via ERBB2 1
lapatinib, placebo, capecitabine, oxaliplatin ERBB2 SSL via ERBB2 1
lonsurf, oxaliplatin, panitumumab, bevacizumab, trastuzumab, nivolumab ERBB2 SSL via ERBB2 1
nab-paclitaxel, gemcitabine, cisplatin, irinotecan, capecitabine, pembrolizumab, olaparib PARP3 SSL via PARP3 1
nal-iri, oxaliplatin, 5-fu, trastuzumab, pembrolizumab, nivolumab ERBB2 SSL via ERBB2 1
nivolumab, tadalafil, oral vancomycin PDE11A SSL via PDE11A 1
olaparib, olaparib, placebo, placebo PARP3 SSL via PARP3 1
olaparib, ramucirumab PARP3 SSL via PARP3 1
olaparib, temozolomide (tmz), imrt (intensity modulated radiation therapy) PARP3 SSL via PARP3 1
olaparib, temozolomide, gene expression analysis, protein expression analysis, laboratory biomarker analysis, pharmacological study, diffusion-weighted magnetic resonance imaging, dynamic contrast-enhanced magnetic resonance imaging, therapeutic conventional surgery PARP3 SSL via PARP3 1
olaparib, temozolomide, irinotecan PARP3 SSL via PARP3 1
oxaliplatin, irinotecan hydrochloride, leucovorin calcium, fluorouracil, ascorbic acid OGFOD1 SSL via OGFOD1 1
oxaliplatin, leucovorin, 5 fluorouracil, trastuzumab, avelumab ERBB2 SSL via ERBB2 1
paclitaxel, bryostatin 1 CCND1 SSL via CCND1 1
palbociclib, afatinib ERBB2 SSL via ERBB2 1
pamiparib, olaparib, radiation therapy, temozolomide PARP3 SSL via PARP3 1
pazopanib, lapatinib ERBB2 SSL via ERBB2 1
pd0332991, anastrozole, goserelin, surgery (standard of care), tumor biopsy GNRHR SSL via GNRHR 1
pembrolizumab, olaparib PARP3 SSL via PARP3 1
pembrolizumab, olaparib, temozolomide PARP3 SSL via PARP3 1
pembrolizumab, placebo, cisplatin, 5-fu, oxaliplatin, capecitabine, s-1, trastuzumab ERBB2 SSL via ERBB2 1
pembrolizumab, tadalafil PDE11A SSL via PDE11A 1
pembrolizumab, trastuzumab, oxaliplatin, capecitabine ERBB2 SSL via ERBB2 1
rucaparib PARP3 SSL via PARP3 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.